Sun launches generic version of Zyprexa
MUMBAI, India — Sun Pharmaceutical Industries has launched a generic version of a drug used to treat psychiatric disorders, the company said.
Sun announced the launch of olanzapine tablets in the 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths.
The drug is a generic version of Eli Lilly’s Zyprexa, used to treat schizophrenia and bipolar disorder. The branded drug and generic versions had sales of $3.28 billion during the 12-month period ended in January, according to IMS Health.
NCPA addresses PDUFA reauthorization
ALEXANDRIA, Va. — The National Community Pharmacists Association has sent a letter to a Senate committee regarding legislation that would reauthorize the Prescription Drug User Fee Act.
In its letter to the Senate Health, Labor, Education and Pensions Committee chairman Tom Harkin, D-Iowa, and ranking member Mike Enzi, R-Wyo., NCPA submitted recommendations to address the views of local pharmacists and NCPA responded to a "manager’s amendment" that would revise the legislation. The organization said its comments focused principally on prescription drug shortages and supply chain integrity.
"We believe the current pharmaceutical supply chain in the United States is safe and secure," NCPA CEO Douglas Hoey said. "As we strive to further strengthen security, there are a number of different approaches or tactics that could be employed. In addition, while most reported drug shortages to date have occurred in hospital settings, community pharmacies are also experiencing shortages, primarily in drugs that treat ADHD. The effects of these shortages could be mitigated by reforming the Drug Enforcement Agency’s quota system and by ensuring that pharmacy reimbursement rates are updated more frequently to reflect price spikes and keep pharmacies whole. In these and other areas, we look forward to continuing to work constructively with Congress as a PDUFA reauthorization is enacted into law this year."
To view the complete letter, click here.
Amgen to buy Turkish drug maker for $700 million
THOUSAND OAKS, Calif. — Biotech drug maker Amgen is buying a pharmaceutical company based in Turkey, the companies said Wednesday.
Amgen said it would acquire 95.6% of Istanbul-based Mustafa Nevzat for $700 million in an all-cash deal, saying the purchase would allow it to expand in Turkey and the surrounding region. The company, also known as MN, is a major supplier of injectable drugs in Turkey and, increasingly, an exporter of medicines.
"Amgen is dedicated to making our innovative medicines available to patients in major markets around the world," Amgen president and CEO Robert Bradway said. "Together with MN’s staff and management team, we plan to grow our business with high-quality and innovative medicines in Turkey and the surrounding region."